Experts are concerned about toxicity in CLL treatment combinations and believe they could challenge established treatment paradigms
Pirtobrutinib (Jaypirca) received FDA full approval in December 2025 for CLL after covalent BTK inhibitor treatment
Liso-cel (lisocabtagene maraleucel) is the first and only FDA-approved CAR-T therapy for relapsed/refractory CLL and SLL as of March 2024
Recent ASH 2025 data shows pirtobrutinib is noninferior to ibrutinib and extends progression-free survival compared to bendamustine-rituximab in frontline CLL
Fixed-duration triplet therapy combining pirtobrutinib, venetoclax, and obinutuzumab yields high rates of undetectable MRD in CLL patients
BTK inhibitors, BCL2 inhibitors, and CD20 monoclonal antibodies are now established first-line treatment options
Non-covalent BTK inhibitors and CAR-T therapies represent emerging options for relapsed CLL and are being investigated for earlier treatment lines